CO2017005391A2 - Composiciones de antibiótico - Google Patents

Composiciones de antibiótico

Info

Publication number
CO2017005391A2
CO2017005391A2 CONC2017/0005391A CO2017005391A CO2017005391A2 CO 2017005391 A2 CO2017005391 A2 CO 2017005391A2 CO 2017005391 A CO2017005391 A CO 2017005391A CO 2017005391 A2 CO2017005391 A2 CO 2017005391A2
Authority
CO
Colombia
Prior art keywords
acetyl
solutions
amino acid
vancomycin
alanine
Prior art date
Application number
CONC2017/0005391A
Other languages
English (en)
Spanish (es)
Inventor
Ivona Jasprica
Sabina Keser
Katarina Pindric
Original Assignee
Xellia Pharmaceuticals Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54478023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2017005391(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xellia Pharmaceuticals Aps filed Critical Xellia Pharmaceuticals Aps
Publication of CO2017005391A2 publication Critical patent/CO2017005391A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CONC2017/0005391A 2014-11-06 2017-05-26 Composiciones de antibiótico CO2017005391A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462076400P 2014-11-06 2014-11-06
US201562168749P 2015-05-30 2015-05-30
PCT/EP2015/075918 WO2016071495A1 (en) 2014-11-06 2015-11-06 Glycopeptide compositions

Publications (1)

Publication Number Publication Date
CO2017005391A2 true CO2017005391A2 (es) 2017-10-31

Family

ID=54478023

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0005391A CO2017005391A2 (es) 2014-11-06 2017-05-26 Composiciones de antibiótico

Country Status (29)

Country Link
US (8) US10188697B2 (https=)
EP (4) EP3215173B8 (https=)
JP (2) JP6797795B2 (https=)
KR (2) KR102763211B1 (https=)
CN (1) CN107073072B (https=)
AU (1) AU2015341763B2 (https=)
BR (1) BR112017009405B1 (https=)
CL (1) CL2017001139A1 (https=)
CO (1) CO2017005391A2 (https=)
CR (1) CR20170234A (https=)
CY (2) CY1122960T1 (https=)
DK (2) DK3542812T3 (https=)
EA (1) EA035368B1 (https=)
ES (2) ES2852550T3 (https=)
HR (2) HRP20200101T1 (https=)
HU (2) HUE053347T2 (https=)
IL (1) IL252120B (https=)
MX (1) MX387229B (https=)
NZ (1) NZ731955A (https=)
PH (1) PH12017500720A1 (https=)
PL (2) PL3542812T3 (https=)
PT (2) PT3542812T (https=)
RS (2) RS59851B1 (https=)
SA (1) SA517381446B1 (https=)
SG (1) SG11201703568WA (https=)
SI (2) SI3215173T1 (https=)
TN (1) TN2017000182A1 (https=)
WO (1) WO2016071495A1 (https=)
ZA (1) ZA201702767B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20200101T1 (hr) 2014-11-06 2020-04-03 Xellia Pharmaceuticals Aps Glikopeptidni pripravci
EP3393491B1 (en) * 2015-12-24 2025-04-16 Universiteit Leiden Composition and method for treating infections caused by vancomycin-resistant infectious agents in a subject
KR20190005940A (ko) * 2016-05-09 2019-01-16 셀리아 파마슈티칼즈 에이피에스 안정화된 글리코펩티드 항생제 제형
RU2019119405A (ru) * 2016-11-23 2020-12-25 Гуфик Байосайенсиз Лимитед Лиофилизированные фармацевтические композиции далбаванцина
JP7118412B2 (ja) * 2017-07-31 2022-08-16 東洋製薬化成株式会社 バンコマイシン懸濁液充填カプセル製剤
CN109725101B (zh) * 2017-10-31 2021-11-19 正大天晴药业集团股份有限公司 盐酸特拉万星原料中有关物质的检测方法
CN109078001B (zh) * 2018-09-21 2021-05-07 深圳浦瑞健康科技有限公司 一种万古霉素纳米脂质体组合物及其制备方法
CA3132923A1 (en) 2019-03-08 2020-09-17 Emphascience, Inc. Stable pharmaceutical formulations of peptide and protein drugs
WO2022031830A1 (en) * 2020-08-04 2022-02-10 Harrow Ip Llc Antibacterial compositions and methods for fabricating thereof
US11433115B2 (en) * 2020-10-30 2022-09-06 Somerset Therapeutics, Llc Glycopeptide antibiotics liquid formulations and methods and uses thereof
EP4014969A1 (en) * 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
EP4014965A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
WO2022234036A1 (en) * 2021-05-07 2022-11-10 Xellia Pharmaceuticals Aps Oral liquid vancomycin formulations
CN115804832A (zh) * 2021-09-14 2023-03-17 海南普利制药股份有限公司 一种万古霉素水溶液组合物
WO2023171588A1 (ja) * 2022-03-08 2023-09-14 国立大学法人大阪大学 抗菌薬を含有するｐｌｇａ製剤
GB202207344D0 (en) 2022-05-19 2022-07-06 Arecor Ltd Novel composition
GB202207345D0 (en) 2022-05-19 2022-07-06 Arecor Ltd Novel composition
AU2023359653A1 (en) * 2022-10-12 2025-05-29 Hikma Pharmaceuticals Usa Inc. Liquid dalbavancin composition
JP2025533237A (ja) * 2022-10-12 2025-10-03 ヒクマ ファーマシューティカルズ ユーエスエイ インコーポレイテッド 液体ダルババンシン組成物
WO2025006267A1 (en) * 2023-06-26 2025-01-02 Venn Biosciences Corporation Peptide biomarkers for diagnosing primary sclerosing cholangitis or primary biliary cholangitis
GB202405996D0 (en) 2024-04-29 2024-06-12 Arecor Ltd Novel compositions
GB202405997D0 (en) 2024-04-29 2024-06-12 Arecor Ltd Novel compositions

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670258A (en) 1984-02-10 1987-06-02 Vanderbilt University Storable prepackaged aqueous solutions of vancomycin
TW457248B (en) 1994-01-28 2001-10-01 Lilly Co Eli Glycopeptide antibiotic derivatives
CA2238872A1 (en) 1995-12-01 1997-06-05 Eli Lilly And Company Stable vancomycin hydrochloride solutions
JPH1180021A (ja) 1997-09-02 1999-03-23 Kayaku:Kk バンコマイシン注射剤
US6800608B2 (en) 2001-06-22 2004-10-05 Beckman Coulter, Inc. Homogeneous assay of vancomycin using a stable particle-vancomycin conjugate, a novel rate enhancer, and a novel dose response modulator
AU2003220585A1 (en) * 2002-03-26 2003-10-13 Arizona Board of Regents on behalf of the University of Arizone Solubilization of weak bases
GB0212622D0 (en) * 2002-05-31 2002-07-10 Natural Technologies Group Ltd Bacterial transforming agent
CN1802090A (zh) * 2002-07-09 2006-07-12 尖端医疗有限公司 硼脯氨酸化合物组合治疗
WO2004004661A2 (en) 2002-07-09 2004-01-15 Point Therapeutics, Inc. Boroproline compound combination therapy
MXPA05005338A (es) 2002-11-18 2005-12-14 Vicuron Pharm Inc Metodos para administrar dalbavancin para el tratamiento de infecciones bacterianas.
CA2597812C (en) 2005-02-14 2012-01-24 Venus Remedies Limited Parenteral combination therapy for infective conditions with drug resistant bacterium
CN1857716A (zh) * 2006-03-14 2006-11-08 浙江大学 注射用盐酸万古霉素及其制备方法
JP2008201778A (ja) * 2007-01-25 2008-09-04 Mochida Pharmaceut Co Ltd バンコマイシン液状製剤
JP2011506442A (ja) * 2007-12-11 2011-03-03 コンジュケム バイオテクノロジーズ インコーポレイテッド インスリン分泌性ペプチド結合体の製剤
JP2011080021A (ja) 2009-10-09 2011-04-21 Bridgestone Corp 熱可塑性エラストマー組成物及びその成形体
JP6012716B2 (ja) * 2011-05-19 2016-10-25 サヴァラ，インク． 乾燥粉末バンコマイシン組成物および関連する方法
US20150182667A1 (en) 2012-08-08 2015-07-02 Vanderbilt University Composition with Biofilm Dispersal Agents
US10124066B2 (en) * 2012-11-29 2018-11-13 Insmed Incorporated Stabilized vancomycin formulations
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
US9616098B2 (en) * 2013-05-30 2017-04-11 Scidose, Llc Formulations of vancomycin
EP4000628B1 (en) 2014-03-14 2025-09-24 Azurity Pharmaceuticals, Inc. Composition and method for vancomycin oral liquid
HRP20200101T1 (hr) * 2014-11-06 2020-04-03 Xellia Pharmaceuticals Aps Glikopeptidni pripravci
KR20190005940A (ko) 2016-05-09 2019-01-16 셀리아 파마슈티칼즈 에이피에스 안정화된 글리코펩티드 항생제 제형
US11433115B2 (en) 2020-10-30 2022-09-06 Somerset Therapeutics, Llc Glycopeptide antibiotics liquid formulations and methods and uses thereof
EP4014965A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
EP4014969A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution

Also Published As

Publication number Publication date
IL252120A0 (en) 2017-07-31
CN107073072A (zh) 2017-08-18
KR102603756B1 (ko) 2023-11-16
CY1122960T1 (el) 2021-10-29
SI3215173T1 (sl) 2020-03-31
AU2015341763B2 (en) 2019-01-17
RS59851B1 (sr) 2020-02-28
AU2015341763A1 (en) 2017-06-08
US10188697B2 (en) 2019-01-29
US11517609B2 (en) 2022-12-06
US20180133286A1 (en) 2018-05-17
IL252120B (en) 2020-07-30
EP3215173B8 (en) 2020-03-11
US20190160142A1 (en) 2019-05-30
US20170348385A1 (en) 2017-12-07
JP6797795B2 (ja) 2020-12-09
HUE053347T2 (hu) 2021-06-28
ZA201702767B (en) 2018-12-19
WO2016071495A1 (en) 2016-05-12
HRP20200101T1 (hr) 2020-04-03
CY1124011T1 (el) 2022-05-27
BR112017009405A2 (pt) 2018-01-02
HRP20210342T8 (hr) 2022-01-21
EP4147710A1 (en) 2023-03-15
KR102763211B1 (ko) 2025-02-04
EP3834837A1 (en) 2021-06-16
US20250288640A1 (en) 2025-09-18
PT3542812T (pt) 2021-04-20
KR20170078830A (ko) 2017-07-07
DK3542812T3 (da) 2021-04-12
US20220354927A1 (en) 2022-11-10
BR112017009405B1 (pt) 2024-02-06
PT3215173T (pt) 2020-04-03
US10849956B2 (en) 2020-12-01
EP3215173A1 (en) 2017-09-13
PH12017500720A1 (en) 2017-10-09
JP7032488B2 (ja) 2022-03-08
RS61418B1 (sr) 2021-03-31
US20210220433A1 (en) 2021-07-22
CR20170234A (es) 2018-01-15
NZ731955A (en) 2023-07-28
KR20230096142A (ko) 2023-06-29
JP2020183424A (ja) 2020-11-12
SG11201703568WA (en) 2017-05-30
CL2017001139A1 (es) 2017-12-01
HUE049857T2 (hu) 2020-10-28
US20230158101A1 (en) 2023-05-25
CA2964524A1 (en) 2016-05-12
US20200069768A1 (en) 2020-03-05
SI3542812T1 (sl) 2021-04-30
US10039804B2 (en) 2018-08-07
EA035368B1 (ru) 2020-06-03
PL3542812T3 (pl) 2021-07-12
ES2769849T3 (es) 2020-06-29
SA517381446B1 (ar) 2020-09-21
EP3542812B1 (en) 2021-01-13
TN2017000182A1 (en) 2018-10-19
US12161690B2 (en) 2024-12-10
JP2017533218A (ja) 2017-11-09
CN107073072B (zh) 2021-06-18
MX2017005749A (es) 2018-01-11
DK3215173T3 (da) 2020-03-23
PL3215173T3 (pl) 2020-05-18
US11000567B2 (en) 2021-05-11
EP3215173B1 (en) 2020-01-01
EA201790997A1 (ru) 2017-09-29
HRP20210342T1 (hr) 2021-04-30
EP3542812A1 (en) 2019-09-25
US11628200B2 (en) 2023-04-18
MX387229B (es) 2025-03-04
ES2852550T3 (es) 2021-09-13

Similar Documents

Publication Publication Date Title
CO2017005391A2 (es) Composiciones de antibiótico
ECSP17078433A (es) Composiciones de ácido obeticólico y métodos de uso
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
SI2958913T1 (sl) Sfingozin-1-fosfat receptor agonisti, postopki za njegovo pripravo in farmacevtski sestavki, ki ga vsebujejo kot aktivno sredstvo
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
EA201591809A1 (ru) Стабилизированный состав витамина d с модифицированным высвобождением и способ его введения
UY35351A (es) Formulaciones acuosas estables de adalimumab
MX2020002693A (es) Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
BR112016006326A2 (pt) formulação seca de uma vacina, uso de uma formulação seca, método para fabricação de uma formulação seca, e, vacina
BR112018002983A2 (pt) composição compreendendo uma lactama e um álcool
MX2016005395A (es) Formulacion estable de insulina glulisina.
MX382747B (es) Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas oncológicas y autoinmunitarias.
GT201700190A (es) Desacetoxitubulisina h y análogos de esta
EP4650000A3 (en) High concentration formulation
BR112017003219A2 (pt) formulação de acetato de abiraterona e métodos de uso
MX389178B (es) Formulacion de proporcion fija de insulina glargina/lixisenatida.
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
MX384877B (es) Composiciones de éster de colina de ácido lipoico y métodos de uso.
MX391152B (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas.
TW201613557A (en) Stable aqueous recombinant protein formulations
BR112017026904A2 (pt) formulações farmacêuticas injetáveis de lefamulina
MX2015005510A (es) Forma salina solida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
EP3135299A4 (en) Active ingredient (i) containing composition and method for preparing same
MX2018004138A (es) Metodos y formulaciones para reducir las emisiones de bovino.